Literature DB >> 12093346

Vascular gene therapy: a reality of the 21st century.

Brian S Zuckerbraun1, Edith Tzeng.   

Abstract

Current therapies for the treatment of atherosclerotic vascular disease are aimed at either disrupting or bypassing flow-limiting lesions. Preventative strategies are necessary to decrease the burden of disease but are limited by genetic predispositions to certain diseases and the body's innate response to injury. Gene therapy, defined as the purposeful therapeutic overexpression or attenuation of a gene product, has enormous potential benefits in vascular disease prevention and treatment strategies. This article reviews the scientific considerations involved in the development of gene therapy strategies and outlines some of the gene products that are currently being used. These interventional genetic approaches will be reviewed in the context of specific vascular disease processes, including atherosclerosis, restenosis, and thrombosis. Gene therapy will serve an enhancing and adjuvant role to evolving surgical therapies.

Entities:  

Mesh:

Year:  2002        PMID: 12093346     DOI: 10.1001/archsurg.137.7.854

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

Review 1.  Molecular imaging of cardiovascular gene products.

Authors:  Joseph C Wu; Jeffrey R Tseng; Sanjiv S Gambhir
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

2.  Evaluation and quantification of angiogenesis activity of terminalia bellirica roxb, by mice sponge implantation method.

Authors:  Vinoth V Prabhu; N Chidambaranathan; V Gopal
Journal:  J Young Pharm       Date:  2012-01

3.  AAV-Mediated Expression of AP-1-Neutralizing RNA Decoy Oligonucleotides Attenuates Transplant Vasculopathy in Mouse Aortic Allografts.

Authors:  Anca Remes; Maximilian Franz; Franziska Mohr; Antje Weber; Kleopatra Rapti; Andreas Jungmann; Matthias Karck; Markus Hecker; Klaus Kallenbach; Oliver J Müller; Rawa Arif; Andreas H Wagner
Journal:  Mol Ther Methods Clin Dev       Date:  2019-10-02       Impact factor: 6.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.